Genes and beans: Pharmacogenomics of renal transplant

Pharmacogenomics

Volumn 14, Issue 7, 2013, Pages 783-798

  Murray, Brian ^a   Hawes, Emily ^a   Lee, Ruth Ann ^b   Watson, Robert ^c   Roederer, Mary W ^a,b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

azathioprine; cyclosporine; everolimus; mycophenolate; pharmacogenetics; pharmacogenomics; sirolimus; tacrolimus; transplantation

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MERCAPTOPURINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ANEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER RISK; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEVER; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; KIDNEY GRAFT; LEUKOPENIA; LIVER TOXICITY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; PAIN; PANCREATITIS; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; REVIEW; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TREMOR; VIRUS INFECTION; VOMITING;

DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84877661095     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.68     Document Type: Review

References (152)

1. De Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant. Rev. (Orlando) 22(1), 6-20 (2008).
2. Sayegh MH, Carpenter CB. Transplantation 50 years later -progress, challenges, and promises. N. Engl. J. Med. 351(26), 2761-2766 (2004).
3. Halloran PF. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351(26), 2715-2729 (2004).
4. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am. J. Transplant. 2(8), 789-795 (2002).
5. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant. Proc. 31(1-2), 296-298 (1999).
6. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman Jr. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349(24), 2326-2333 (2003).
7. Davidson JA, Wilkinson A. New-onset diabetes after transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care 27(3), 805-812 (2004).
8. De Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther. Drug Monit. 31(4), 416-435 (2009).
9. Holt DW. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr. Opin. Nephrol. Hypertens. 11(6), 657-663 (2002).
10. Kahan BD, Napoli KL, Podbielski J, Hussein I, Katz SH, Van Buren CT. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes. Transplant. Proc. 33(1-2), 1278 (2001).
11. Ekbal NJ, Holt DW, MacPhee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics 9(5), 585-596 (2008).
12. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9(Suppl. 3), S1-S157 (2009).
13. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J. Heart Lung Transplant. 29(8), 914-956 (2010).
14. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 331(7520), 810 (2005).
15. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 80(Suppl. 2), S235-S243 (2005).
16. Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 87(6), 785-794 (2009).
17. Speich R, Schneider S, Hofer M, et al. Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation. Pulm. Pharmacol. Ther. 23(5), 445-449 (2010).
18. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am. J. Transplant. 3(1), 68-73 (2003).
19. Germani G, Pleguezuelo M, Villamil F, et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am. J. Transplant. 9(8), 1725-1731 (2009).
20. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 364(9433), 503-512 (2004).
21. Remuzzi G, Cravedi P, Constantini M, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J. Am. Soc. Nephrol. 18(6), 1973-1985 (2007).
22. Clayton PA, McDonald SP, Chapman JR, Chadban SJ. Mycophenolate versus azathioprine for kidney transplantation: a 15 year follow-up of a randomized trial. Transplantation 94(2), 152-158 (2012).
23. Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88(Suppl. 3), S62-S67 (2009).
24. Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am. J. Health Syst. Pharm. 63(23), 2340-2348 (2006).
25. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet. 49(3), 141-175 (2010).
26. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab. Pharmacokinet. 22(5), 328-335 (2007).
27. Barry A, Levine M. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients. Ther. Drug Monit. 32(6), 708-714 (2010).
28. MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002).
29. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Tranpslant. 4(6), 914-919 (2004).
30. Hesselink DA, van Schaik R, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
31. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8), 1233-1235 (2003).
32. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR-1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007).
33. Tavira B, Coto E, Diaz-Corte C, et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med. 49(5), 825-833 (2011).
34. Jacobson PA, Oetting WW, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 91(3), 300-308 (2011).
35. Santoro A, Felipe CR, Tedesco-Silva H, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 12(9), 1293-1303 (2011).
36. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet. Genomics 18(4), 339-348 (2008).
37. Ferraresso M, Turolo S, Ghio L, et al. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors. Clin. Exp. Hypertens. 33(6), 359-365 (2011).
38. Zheng S, Tasnif Y, Hebert MF, et al. Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin. Pharmacol. Ther. 92(6), 737-745 (2012).
39. Wang P, Mao Y, Razo J, et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 11(10), 1389-1402 (2010).
40. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72(6), 948-957 (2011).
41. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010).
42. Miura M, Satoh S, Kagaya H, et al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12(7), 977-984 (2011).
43. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12(10), 1383-1396 (2011).
44. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 14(1), 47-62 (2013).
45. Laverdiere I, Caron P, Harvey M, Levesque E, Guillemette C. In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. Drug Metab. Dispos. 39(7), 1127-1130 (2011).
46. De Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12(9), 1281-1291 (2011).
47. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin. Pharmacokinet. 48(12), 805-816 (2009).
48. Barraclough KA, Isbel NM, Lee KJ, et al. NR112 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. Transplantation 94(10), 1025-1032 (2012).
49. Moore J, McKnight AJ, Dohler B, et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J. Am. Soc. Nephrol. 23(11), 1891-1899 (2012).
50. Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91(6), 1044-1052 (2012).
51. Herrero MJ, Sanchez-Plumed J, Galiana M, Bea S, Marques MR, Alino SF. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. Transplant. Proc. 42(8), 3134-3136 (2010).
52. Lopez-Montenegro Soria MA, Kanter Berga J, Beltran Catalan S, Milara Paya J, Pallardo Mateu LM, Jimenez Torres NV. Genetic polymorphisms and individualized tacrolimus dosing. Transplant. Proc. 42(8), 3031-3033 (2010).
53. Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics 11(5), 703-714 (2010).
54. Wu P, Ni X, Wang M, Xu X, Luo G, Jiang Y. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. Ann. Transplant. 16(1), 54-60 (2011).
55. Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant. Proc. 42(9), 3455-3458 (2010).
56. Zheng HX, Zeevi A, McCurry K, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl. Immunol. 14(1), 37-42 (2005).
57. Barnard JB, Richardson S, Sheldon S, et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation 82(12), 1677-1682 (2006).
58. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 86(9), 1206-1213 (2008).
59. Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transplant. Int. 21(9), 879-891 (2008).
60. Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, Mcelnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br. J. Clin. Pharmacol. 68(3), 413-421 (2009).
61. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histologic damage in renal allografts. J. Am. Soc. Nephrol. 20(11), 2468-2480 (2009).
62. Yamauchi A, Ieiri I, Kataoka Y, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74(4), 571-572 (2002).
63. Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther. Drug Monit. 32(4), 387-393 (2010).
64. Shuker N, Bouamar R, Weimar W, van Schaik RH, van Gelder T, Hesselink DA. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin. Chim. Acta 413(17-18), 1326-1337 (2012).
65. Tavira B, Coto E, Torres A, et al. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with tacrolimus. Mol. Genet. Metab. 105(3), 525-527 (2012).
66. Tavira B, Coto E, Diaz-Corte C, et al. KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients. Clin. Transplant. 25(3), E284-E291 (2011).
67. Eng HS, Mohamed Z, Calne R, et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int. 69(10), 1858-1864 (2006).
68. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004).
69. Hu YF, Qiu W, Liu ZQ, et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin. Exp. Pharmacol. Physiol. 33(11), 1093-1098 (2006).
70. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 14(10), 665-671 (2004).
71. Zhao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant. Proc. 37(1), 178-181 (2005).
72. Hu YF, Tu JH, Tan ZR, et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 37(3), 315-327 (2007).
73. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13(2), 89-95 (2003).
74. Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5), 373-388 (2000).
75. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47(6), 1048-1052 (2001).
76. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics 22(5), 373-380 (2012).
77. Moscoso-Soloranzo GT, Ortega F, Rodriguez I, et al. A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients. Clin. Transplant. 22(6), 722-729 (2008).
78. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur. J. Clin. Pharmacol. 66(6), 579-590 (2010).
79. Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76(6), 545-556 (2004).
80. Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch. Pharmacol. 380(2), 169-177 (2009).
81. Singh R, Kesarwani P, Srivastava A, Mittal RD. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India. Arch. Med. Res. 39(7), 695-701 (2008).
82. Foote CJ, Greer W, Kiberd B, et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 83(10), 1380-1384 (2007).
83. Azarpira N, Aghdaie MH, Behzad-Behbahanie A, et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp. Clin. Transplant. 4(1), 416-419 (2006).
84. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 43(6), 555-564 (2003).
85. Hebert MF, Dowling AL, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13(11), 661-674 (2003).
86. Cattaneo D, Ruggenenti P, Baldelli S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J. Am. Soc. Nephrol. 20(6), 1404-1415 (2009).
87. Woillard JB, Rerolle JP, Picard N, et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin. Pharmacol. Ther. 88(1), 95-100 (2010).
88. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16(5), 1501-1511 (2005).
89. Hauser IA, Kruck S, Gauer S, et al. Human pregnane x receptor genotype of the donor but not of the recipient is a risk factor for delayed graft function after renal transplantation. Clin. Pharmacol. Ther. 91(5), 905-916 (2012).
90. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81(9), 1234-1248 (2006).
91. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 59(1), 3-16 (2001).
92. Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 30(10), 1044-1056 (2010).
93. Ingle GR, Sievers TM, Holt CD. Sirolimus: continuing the evolution of transplant immunosuppression. Ann. Pharmacother. 34(9), 1044-1055 (2000).
94. Djebli N, Rousseau A, Rerolle JP, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modeling in kidney transplant recipients. Clin. Pharmacokinet. 45(11), 1135-1148 (2006).
95. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin. Pharmacol. Ther. 80(1), 51-60 (2006).
96. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin. Transplant. 25(1), 146-150 (2011).
97. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43(4), 329-339 (1992).
98. Aarbakke J, Janka-Schaub G, Elion GB. Thiopurine biology and pharmacology. Trends Pharmacol. Sci. 18(1), 3-7 (1997).
99. Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther. 312(2), 537-545 (2005).
100. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. 111(8), 1133-1145 (2003).
101. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J. Clin. Pathol. 63(4), 288-295 (2010).
102. Van Os EC, Zins BJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 39(1), 63-68 (1996).
103. Odlind B, Hartvig P, Lindstrom B, Lonnerholm G, Tufveson G, Grefberg N. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. Int. J. Immunopharmacol. 8(1), 1-11 (1986).
104. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol. 30(4), 358-363 (1990).
105. Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can. J. Gastroenterol. 12(7), 479-483 (1998).
106. Singh G, Fries JF, Spitz P, et al. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum. 32(7), 837-843 (1989).
107. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011).
108. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11(2), 177-188 (2010).
109. Reuther LO, Vainer B, Sonne J, Larsen NE. Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur. J. Clin. Pharmacol. 59(11), 797-801 (2004).
110. Pandya B, Thomson W, Poulton K, Bruce I, Payne D, Qasim F. Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients. Transplant. Proc. 34(5), 1642-1645 (2002).
111. Fabre MA, Jones DC, Bunce M, et al. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Transpl. Int. 17(9), 531-539 (2004).
112. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53(5), 1051-1056 (1992).
113. Formea CM, Myers-Huentelman H, Wu R, et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am. J. Transplant. 4(11), 1810-1817 (2004).
114. Song DK, Zhao J, Zhang LR. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment. J. Clin. Pharm. Ther. 31(6), 627-635 (2006).
115. Sebbag L, Boucher P, Davelu P, et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 69(7), 1524-1527 (2000).
116. Heckmann JM, Lambson EM, Little F, Owen EP. Thiopurine methyltransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J. Neurol. Sci. 231(1-2), 71-80 (2005).
117. Dervieux T, Medard Y, Baudouin V, et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. Br. J. Clin. Pharmacol. 48(6), 793-800 (1999).
118. Thervet E, Anglicheau D, Toledano N, et al. Long-term results of TPMT activity monitoring in azathioprine-treated renal allograft recipients. J. Am. Soc. Nephrol. 12(1), 170-176 (2001).
119. Thervet E, Anglicheau D, Toledano N, et al. Clinical consequences of the polymorphism of azathioprine metabolism. Transplant. Proc. 32(8), 2780 (2000).
120. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin. Immunopathol. 14(4), 353-380 (1993).
121. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 56(1), 75-82 (1993).
122. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin. Pharmacol. Ther. 66(5), 492-500 (1999).
123. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther. Drug Monit. 22(1), 27-30 (2000).
124. Jacobson PA, Schladt D, Oetting WS, et al. Genetic determinants of mycophenolate-related anemia and leucopenia after transplantation. Transplantation 91(3), 309-316 (2011).
125. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9(1), 19-33 (2008).
126. Michelon H, Konig J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 11(12), 1703-1713 (2010).
127. Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(12), 1161-1169 (2007).
128. Picard N, Yee SW, Woillard JB, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther. 87(1), 100-108 (2010).
129. Bouamar R, Hesselink DA, van Schaik RH, et al. Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet. Genomics 22(6), 399-407 (2012).
130. Hesselink DA, van Hest RM, Mathot R, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. 5(5), 987-994 (2005).
131. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J. Pharmacol. Exp. Ther. 309(3), 1029-1035 (2004).
132. Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab. Dispos. 34(2), 261-266 (2006).
133. Naesens M, Kuypers D, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82(8), 1074-1084 (2006).
134. Sanchez-Fructuoso AI, Maestro ML, Calvo N, et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant. Proc. 41(6), 2313-2316 (2009).
135. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 78(4), 351-361 (2005).
136. Kuypers DR, De Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5 year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin. Ther. 30(4), 673-683 (2008).
137. van Schaik RH, van Agteren M, De Fijter JW, et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther. 86(3), 319-327 (2009).
138. Johnson LA, Oetting WS, Basu S, Prausa S, Matas A, Jacobson PA. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur. J. Clin. Pharmacol. 64(11), 1047-1056 (2008).
139. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit. 28(2), 145-154 (2006).
140. Woillard JB, Rerolle JP, Picard N, et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele. Br. J. Pharmacol. 69(6), 675-683 (2010).
141. Kagaya H, Inoue K, Miura M, et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63(3), 279-288 (2007).
142. Zhang WX, Chen B, Jin Z, et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 38(11), 1422-1436 (2008).
143. Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8(9), 1127-1141 (2007).
144. Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther. Drug Monit. 31(5), 542-548 (2009).
145. van Agteren M, Armstrong VW, van Schaik RH, et al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther. Drug Monit. 30(4), 439-444 (2008).
146. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet. Genomics 17(5), 321-330 (2007).
147. Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 11(3), 369-390 (2010).
148. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin. Pharmacol. Ther. 83(5), 711-717 (2008).
149. Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet. Genomics 19(8), 626-634 (2009).
150. The National Library of Medicine -PROGRAF (tacrolimus) labeling information. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f667de1- 9dfa-4bd6-8ba0-15ee2d78873b#nlm34084-4 (Accessed 2 July 2012)
151. The National Library of Medicine -IMURAN (azathioprine) labeling information. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=46199 (Accessed 2 July 2012)
152. The National Library of Medicine -CELLCEPT (mycophenolate) labeling information. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81ca6530- 76d1-46f1-9bf8-0ffac79d2523 (Accessed 24 June 2012)